December 6, 2017

Neumentum, a pharmaceutical company dedicated to transforming the way acute and chronic pain are treated – without opioids – announced that is has raised $6 million in a Series A funding round through the sale of Series A Convertible Preferred Stock.  The funding will be used to advance a pipeline of non-opioid drug candidates that have the potential to treat pain, without the risks of abue, misuse and diversion frequently associated with opioids.  Learn more here.